Pharma: Page 33

  • Brain puzzle
    Image attribution tooltip
    designer491 via Getty Images
    Image attribution tooltip

    Overcoming mental health’s drug development challenges with AI

    PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.

    By Kelly Bilodeau • Aug. 23, 2022
  • Brian Goff stands laughing in the forefront, with a crowded room of business attire-clad people in the background.
    Image attribution tooltip

    Permission granted by Brian Goff. 

    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Agios Pharmaceuticals’ Brian Goff

    The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

    By Alexandra Pecci • Aug. 22, 2022
  • clinical trial diversity Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Clinical trial diversity

    As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

    By PharmaVoice staff
  • Money pills
    Image attribution tooltip
    cagkansayin via Getty Images
    Image attribution tooltip

    Patents, pandemics and pricing: a peek at the top drug from every big pharma

    A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

    By • Aug. 22, 2022
  • President Biden signs the Inflation Reduction Act surrounded by members of congress and backed by American flags in the White House.
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    3 ways pharma can prep for Biden’s sweeping drug pricing policies

    Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

    By Karissa Waddick • Aug. 18, 2022
  • Teresa Bitetti Takeda Oncology
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Takeda Oncology’s Teresa Bitetti

    Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.

    By • Aug. 17, 2022
  • George Magrath wears blue scrubs and sits over a patient.
    Image attribution tooltip

    Permission granted by George Magrath. 

    Image attribution tooltip

    The CEO in the ophthalmologist’s coat

    In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

    By Alexandra Pecci • Aug. 16, 2022
  • Nasal spray
    Image attribution tooltip
    Evgenyi_Eg via Getty Images
    Image attribution tooltip

    Right under our noses: Could COVID-19 vaccines be better as nasal spray?

    Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

    By Kelly Bilodeau • Aug. 16, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    The FDA is mulling an OTC approval for a birth control. Will politics factor in?

    Analysts are watching how cultural and political debates around reproductive rights may impact HRA Pharma's OTC birth control application.

    By Karissa Waddick • Aug. 15, 2022
  • ARLINGTON, VA - JUNE 05: Recently laid off worker Lyn Talent receives a free Botox injection during an event called the "The Botox Bailout."
    Image attribution tooltip
    Win McNamee/Staff via Getty Images
    Image attribution tooltip

    Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics

    Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.

    By • Aug. 11, 2022
  • A doctor and a businessperson shaking hands.
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By • Aug. 11, 2022
  • cell therapy infusion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By • Aug. 10, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    How real world evidence is impacting rare disease drug development

    ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

    By Kim Ribbink • Aug. 9, 2022
  • A baby harp seal pup lays on ice in the White Sea.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

    With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

    By Alexandra Pecci • Aug. 9, 2022
  • CEO pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Are Big Pharma CEOs earning their pay?

    While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

    By Kelly Bilodeau • Aug. 8, 2022
  • monkeypox vax
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    The ‘alarming’ spread of Monkeypox — by the numbers

    With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

    By • Aug. 8, 2022
  • Pills, blister packs, medical bottles, laptop
    Image attribution tooltip
    MJ_Prototype via Getty Images
    Image attribution tooltip

    Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

    Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.

    By • Aug. 4, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Image attribution tooltip
    Making Moves

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Karissa Waddick • Aug. 3, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Taking probiotics where they’ve never gone before

    How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

    By Karissa Waddick • Aug. 2, 2022
  • A physician in a white scrubs assists a blue-shirted patient.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

    EverythingALS aims to speed drug development through improved diagnostics.

    By Kelly Bilodeau • Aug. 2, 2022
  • Artifical intelligence
    Image attribution tooltip
    Olemedia via Getty Images
    Image attribution tooltip
    Q&A

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • Catherine Owen
    Image attribution tooltip

    Permission granted by Catherine Owen.

    Image attribution tooltip
    Q&A

    A glimpse inside Bristol Myers Squibb’s integration with Celgene

    Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

    By • Aug. 1, 2022
  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Giuseppe Lombardo via Getty Images
    Image attribution tooltip
    Q&A

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    By Karissa Waddick • July 28, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By • July 27, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Democrats think they've found a balance between drug innovation and pricing negotiation

    A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

    By Karissa Waddick • July 26, 2022
  • Neuron
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

    The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

    By • July 25, 2022